SCHEMBL6355052

SCHEMBL6355052

NC(=O)c1nn(-c2ccc(S(N)(=O)=O)cc2)c2c1ccc1ccc(NC(=O)c3cccnc3)cc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.48
ALDH1A1 P00352 5/20 0.46
NPC1 O15118 4/20 0.46
RAB9A P51151 4/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
KHK P50053 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
BRAF P15056 1/20 0.45
EPHX2 P34913 2/20 0.43
KDM4E B2RXH2 2/20 0.43
POLB P06746 2/20 0.43
LMNA P02545 1/20 0.43
PTGS2 P35354 1/20 0.43
MAPT P10636 2/20 0.43
MAPK1 P28482 1/20 0.43
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6345689 0.89 CA9 (0.44) MEN1KMT2AKHKEPHX2LMNA
SCHEMBL6342797 0.86 PTGS2 (0.48) L3MBTL1NPC1RAB9AMEN1KMT2A
SCHEMBL6343217 0.86 PTGS2 (0.47) L3MBTL1ALDH1A1NPC1RAB9AMEN1
SCHEMBL6353488 0.86 ALDH1A1 (0.48) L3MBTL1ALDH1A1NPC1RAB9AMEN1
SCHEMBL6342790 0.85 PTGS2 (0.50) EPHX2LMNAPTGS2MAPTCA12
SCHEMBL6343380 0.84 PTGS2 (0.49) ALDH1A1NPC1RAB9AMEN1KMT2A
SCHEMBL6343563 0.84 CA1 (0.49) L3MBTL1ALDH1A1MEN1KMT2ABRAF
SCHEMBL6342695 0.83 IKBKB (0.51) ALDH1A1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL6342102 0.82 CA2 (0.48) ALDH1A1PTGS2MAPTCA12CA1
SCHEMBL6344535 0.82 KMT2A (0.54) KMT2AEPHX2PTGS2CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1438293-A2 SUBSTITUTED PYRAZOLYL BENZENESULFAMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2004-07-21 EP claimed
US-20030125361-A1 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-07-03 US claimed
WO-2003027075-A2 SUBSTITUTED PYRAZOLYL BENZENESULFAMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2003-04-03 WO claimed
US-6849653-B2 1H-benzo(g)indazole compounds as anticarcinogenic agents and also treat arthritis PHARMACIA CORPORATION (US) 2005-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125361-A1 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation IRAK4, NLRP3, CXCL8 L3MBTL1 4165/4885ALDH1A1 1056/4885NPC1 3782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.